A Phase II Double-Blind Multicentre, Placebo-Controlled Trial to Assess the Efficacy and Safety of Alpelisib (BYL719) in Paediatric and Adult Patients with Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP): the SESAM Study Protocol